Apixaban for Extended Treatment of Venous ThromboembolismAGNELLI, Giancarlo; BULLER, Harry R; COHEN, Alexander et al.The New England journal of medicine. 2013, Vol 368, Num 8, pp 699-708, issn 0028-4793, 10 p.Article

Apixaban Metabolism and Pharmacokinetics after Oral Administration to HumansRAGHAVAN, Nirmala; FROST, Charles E; DONGLU ZHANG et al.Drug metabolism and disposition. 2009, Vol 37, Num 1, pp 74-81, issn 0090-9556, 8 p.Article

Impact of apixaban on routine and specific coagulation assays: a practical laboratory guideDOUXFILS, Jonathan; CHATELAIN, Christian; CHATELAIN, Bernard et al.Thrombosis and haemostasis. 2013, Vol 110, Num 2, pp 283-294, issn 0340-6245, 12 p.Article

Bon usage d'apixaban: que retenir pour la pratique = Proper use of apixaban: An outline for clinical practiceALBALADEJO, P; DEPLANQUE, D; FOSSATI, F et al.Journal des maladies vasculaires. 2014, Vol 39, Num 6, pp 409-425, issn 0398-0499, 17 p.Article

Oral Apixaban for the Treatment of Acute Venous ThromboembolismAGNELLI, Giancarlo; BULLER, Harry R; WEITZ, Jeffrey I et al.The New England journal of medicine. 2013, Vol 369, Num 9, pp 799-808, issn 0028-4793, 10 p.Article

Sulfation of Ο-Demethyl Apixaban : Enzyme Identification and Species ComparisonLIFEI WANG; RAGHAVAN, Nirmala; KAN HE et al.Drug metabolism and disposition. 2009, Vol 37, Num 4, pp 802-808, issn 0090-9556, 7 p.Article

Tissue Distribution and Elimination of [¹⁴C]Apixaban in RatsLIFEI WANG; KAN HE; MAXWELL, Brad et al.Drug metabolism and disposition. 2011, Vol 39, Num 2, pp 256-264, issn 0090-9556, 9 p.Article

In Vitro Assessment of Metabolic Drug-Drug Interaction Potential of Apixaban through Cytochrome P450 Phenotyping, Inhibition, and Induction StudiesLIFEI WANG; DONGLU ZHANG; HUMPHREYS, W. Griffith et al.Drug metabolism and disposition. 2010, Vol 38, Num 3, pp 448-458, issn 0090-9556, 11 p.Article

A NEW ERA OF ANTICOAGULATIONHAINAUT, P. H.Acta clinica belgica (English ed.). 2012, Vol 67, Num 6, pp 394-398, issn 1784-3286, 5 p.Article

Nouveaux anticoagulants: ont-ils déjà une place en oncologie ? : Thrombose et cancer = Novel anticoagulants: do they already have a place in oncology departments ? : Thrombosis and cancerDICATO, M; PLAWNY, L.Oncologie (Paris). 2012, Vol 14, Num 12, pp 659-662, issn 1292-3818, 4 p.Article

Apixaban versus enoxaparin in patients with total knee arthroplasty: A meta-analysis of randomised trialsJIAHAO HUANG; YUNFEI CAO; CUN LIAO et al.Thrombosis and haemostasis. 2011, Vol 105, Num 2, pp 245-253, issn 0340-6245, 9 p.Article

Place des nouveaux anticoagulants oraux en salle de cardiologie interventionnelle = Role of new anticoagulants in interventional cardiologyBRASSELET, C; DUVAL, S.Annales de cardiologie et d'angéiologie (Paris). 2012, Vol 61, Num 6, pp 453-456, issn 0003-3928, 4 p.Article

Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of apixaban in healthy Japanese male subjectsYAMAHIRA, Naomi; FROST, Charles; FUKASE, Hiroyuki et al.International journal of clinical pharmacology and therapeutics. 2014, Vol 52, Num 7, pp 564-573, issn 0946-1965, 10 p.Article

Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitorHE, Kan; LUETTGEN, Joseph M; WEXLER, Ruth R et al.European journal of drug metabolism and pharmacokinetics. 2011, Vol 36, Num 3, pp 129-139, issn 0378-7966, 11 p.Article

Antagonisation des héparines et des nouveaux anticoagulants = Reversal for heparins and new anticoagulant treatmentsKORTCHINSKY, T; VIGUE, B; SAMAMA, C. M et al.Annales françaises d'anesthésie et de réanimation. 2013, Vol 32, Num 1, pp 37-49, issn 0750-7658, 13 p.Article

Apixaban in patients with atrial fibrillation and prior coronary artery disease: Insights from the ARISTOTLE trialBAHIT, Maria Cecilia; LOPES, Renato D; HANNA, Michael et al.International journal of cardiology. 2013, Vol 170, Num 2, pp 215-220, issn 0167-5273, 6 p.Article

Oral Direct Factor Xa InhibitorsYEH, Calvin H; FREDENBURGH, James C; WEITZ, Jeffrey I et al.Circulation research. 2012, Vol 111, Num 8, pp 1069-1078, issn 0009-7330, 10 p.Article

Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assayBARRETT, Yu Chen; ZHAOQING WANG; FROST, Charles et al.Thrombosis and haemostasis. 2010, Vol 104, Num 6, pp 1263-1271, issn 0340-6245, 9 p.Article

Apixaban: First Global ApprovalWATSON, Julia; WHITESIDE, Glen; PERRY, Caroline et al.Drugs (Basel). 2011, Vol 71, Num 15, pp 2079-2089, issn 0012-6667, 11 p.Article

Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays: A multicentre French GEHT studyGOUIN-THIBAULT, Isabelle; FLAUJAC, Claire; DELAVENNE, Xavier et al.Thrombosis and haemostasis. 2014, Vol 111, Num 2, pp 240-248, issn 0340-6245, 9 p.Article

Safety of new oral anticoagulant drugs: a perspectiveVILCHEZ, Juan Antonio; GALLEGO, Pilar; LIP, Gregory Y. H et al.Therapeutic advances in drug safety (Print). 2014, Vol 5, Num 1, pp 8-20, issn 2042-0986, 13 p.Article

Nouveaux anticoagulants oraux: mécanisme d'action et données pharmacocinétiques = New oral anticoagulants: mechanism of action and pharmacokinetic propertiesDELAVENNE, X; ZUFFEREY, P.La Lettre du pharmacologue (Boulogne). 2012, Vol 26, Num 3, pp 78-82, issn 0984-452X, 5 p.Article

Oral anticoagulation with factor Xa and thrombin inhibitors: on the threshold of changeCARREIRO ZIKRIA, Jennifer; ANSELL, Jack.Current opinion in hematology. 2009, Vol 16, Num 5, pp 347-356, issn 1065-6251, 10 p.Article

Interpretation of endpoints in a network meta-analysis of new oral anticoagulants following total hip or total knee replacement surgeryHARENBERG, Job; MARX, Svetlana; DAHL, Ola E et al.Thrombosis and haemostasis. 2012, Vol 108, Num 5, pp 909-918, issn 0340-6245, 10 p.Article

Novel oral anticoagulants - key messages for the angiologistHAAS, Sylvia; SPANNAGL, Michael; SCHELLONG, Sebastian M et al.VASA (Bern). 2012, Vol 41, Num 3, pp 177-191, issn 0301-1526, 15 p.Article